Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2002

View Archived Issues

Radiopharmaceutical therapy reduces pain with low toxicity in osteosarcoma patients

Effects on dendritic cell function of the immunomodulator R-848

Topical application of NF-kB decoy ODN successfully treats atopic dermatitis

Effective, safe, rapid and long-lasting relief of allergic symptoms achieved with tecastemizole

GI safety of Merck's new-generation COX-2-selective agent etoricoxib

Aventis reflects on achievements in 2001

Hepatoprotective effects of iNOS inhibitor Ono-1714 demonstrated in pig I/R model

PDE5 inhibitor reduces elevated lower esophageal sphincter tone in humans

Encouraging results obtained for Vasogen's immune modulation therapy in CHF

Corixa's Melacine phase III design approved

D-Pharm earns first milestone payment for SPD-421 from Shire

Endostatin designated orphan drug in malignant metastatic melanoma

Inhaled antimicrobial agent to be screened for potential against anthrax

OrBec receives orphan drug status in Europe for intestinal graft-vs.-host disease

NDA filed for Zomig Nasal Spray

Achillion initiates phase II trial of ACH-126443 in HBV

Oxigene and Peregrine conclude Arcus Therapeutics joint venture

Procleix HIV-1/HCV NAT assay approved in U.S.

Potential of new arthroscopy drug validated in phase II clinical trials

Scientists at Genentech describe c-mpl agonist antibodies

Tetracycline compounds with antibacterial activity

Compounds for use in diseases associated with hypercholesterolemia described by BASF

Histamine H3 receptor ligands reportedly useful for Alzheimer's disease, etc.

Italian researchers identify compounds with potential in the treatment of HCV infection

Factor Xa and/or factor VIIa inhibitors in the Merck pipeline

Roche synthesizes prodrugs of 4-phenylpyridine tachykinin NK1 receptor antagonists

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...